Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys

被引:19
作者
Ohmura, T [1 ]
Chachin, M
Tarui, S
Nagakura, A
Igarashi, T
Ikeda, H
Ikegami, K
Kitagawa, H
Uchida, S
机构
[1] Nippon Boehringer Ingelheim, Kawanishi Pharma Res Inst, Dept Pharmacol, Kawanishi 6660193, Japan
[2] Nippon Boehringer Ingelheim, Kawanishi Pharma Res Inst, Dept Drug Metab & Pharmacokinet, Kawanishi 6660193, Japan
[3] Environm Biol Life Sci Res Ctr, Shiga 5280052, Japan
[4] Nippon Boehringer Ingelheim, Prod Management Dept, Kawanishi 6660193, Japan
关键词
histamine H-1 receptor antagonist; terfenadine; astemizole; epinastine; cynomolgus monkey; ECG (electrocardiogram);
D O I
10.1016/S0014-2999(99)00457-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined the effects of non-sedative histamine H-1 receptor antagonists on the electrocardiogram (ECG) in conscious cynomolgus monkeys. Terfenadine (3 mg kg(-1) h(-1), i.v.) and astemizole (0.3 and 1 mg kg(-1) h(-1), i.v.) caused significant time-dependent increases in the QT interval and QTc Bazett (QTc). However, normal ECG forms were found during a 60-min infusion of epinastine (3 mg kg(-1) h-' i.v.), A higher dose of epinastine (10 mg kg(-1) h-', i.v.) increased the QTc and PR interval only 5 min after the start of the infusion. The minimum plasma concentrations of terfenadine, astemizole and epinastine which caused QTc prolongation were 85, 35 and over than 3600 ng/ml, respectively. These drugs did not alter the PQ and QRS intervals and did not cause arrhythmia or atrioventricular block. Our results are consistent with the clinical observation that prolongation of QTc is caused by terfenadine and astemizole but not by epinastine. Thus, measurement of QTe in cynomolgus monkey appears to be a useful approach for evaluating the potential cardiotoxicity of histamine H-1, receptor antagonists. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 31 条
[1]   Systemic antifungal agents - Drug interactions of clinical significance [J].
Albengres, E ;
Le Louet, H ;
Tillement, JP .
DRUG SAFETY, 1998, 18 (02) :83-97
[2]  
Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
[3]   IS QT INTERVAL PROLONGATION HARMFUL - A REGULATORY PERSPECTIVE [J].
BOTSTEIN, P .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (06) :B50-B52
[4]  
CHACHIN M, 1998, COMP STUDIES EPINAST, P18
[5]  
CONTI CR, 1994, CLIN CARDIOL, V17, P1
[6]  
ESTELLE R, 1990, J ALLERGY CLIN IMMUN, V86, P995
[7]  
GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185
[8]   The role of ketoconazole in the QTc interval prolonging effects of H-1-antihistamines in a guinea-pig model of arrhythmogenicity [J].
Gras, J ;
Llenas, J ;
Palacios, JM ;
Roberts, DJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (02) :187-188
[9]  
Hey JA, 1996, ARZNEIMITTEL-FORSCH, V46, P159
[10]   CHANGES IN THE PHARMACOKINETICS AND ELECTROCARDIOGRAPHIC PHARMACODYNAMICS OF TERFENADINE WITH CONCOMITANT ADMINISTRATION OF ERYTHROMYCIN [J].
HONIG, PK ;
WOOSLEY, RL ;
ZAMANI, K ;
CONNER, DP ;
CANTILENA, LR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (03) :231-238